Some Most Unpredictable Shares UPDATE (CSIQ, STP, KWK, DVAX)

New York, NY -- (SBWIRE) -- 01/09/2013 -- Dynavax Technologies Corporation (NASDAQ:DVAX) shares increased 4.44% to $3.06 in yesterday’s session. J.P. Morgan & Co. initiated coverage on Dynavax with a Neutral rating on Jan. 2. J.P. Morgan initiated coverage of Dynavax (DVAX) with a Neutral rating. Dynavax is a clinical stage biotechnology company with a focus on infectious and inflammatory diseases. The company has a number of interesting early-stage candidates in the pipeline, but the key potential value driver is the lead asset HEPLISAV, which has been submitted to the FDA for the active immunization against all subtypes of hepatitis B virus infection in adults 18-70 years of age.

Will DVAX Bounce Back? Get Free Trend Analysis Here

Suntech Power Holdings Co., Ltd. (ADR) (NYSE:STP) shares increased 12.16% to $1.66. The company, on Dec. 18, announced that its solar modules have passed the Blowing Sand Test based on DIN EN 60068-2-68 LC2 by SGS, the world’s leading inspection, verification, testing and certification company. The SGS test result confirms that Suntech’s solar modules are suitable for solar installations in desert regions.

Can STP Continue To Move Lower After The Recent Gain and Investors Can Make Money? Find Out Here

Quicksilver Resources Inc (NYSE:KWK) shares increased 3.82 to $2.99. The company, on Jan. 3, announced it closed the previously-announced Acquisition and Exploration Agreement (the “Agreement”) with SWEPI LP, a subsidiary of Royal Dutch Shell plc, on December 28, 2012. Quicksilver now owns a 50% interest in approximately 320,000 net acres in the Sand Wash Basin in Northwest Colorado, which will be jointly developed with SWEPI.

Will KWK Bounce Back? Get Free Trend Analysis Here

Dynavax Technologies Corporation (NASDAQ:DVAX) shares increased 4.44% to $3.06 in yesterday’s session. J.P. Morgan & Co. initiated coverage on Dynavax with a Neutral rating on Jan. 2. J.P. Morgan initiated coverage of Dynavax (DVAX) with a Neutral rating. Dynavax is a clinical stage biotechnology company with a focus on infectious and inflammatory diseases. The company has a number of interesting early-stage candidates in the pipeline, but the key potential value driver is the lead asset HEPLISAV, which has been submitted to the FDA for the active immunization against all subtypes of hepatitis B virus infection in adults 18-70 years of age.

Will DVAX Bounce Back? Get Free Trend Analysis Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz